These findings along with prior studies revealing the renoprotective activity of GTS-21 and other cholinergic agonists strongly support additional pre-clinical studies exploring the therapeutic potential of α7nAChR agonists, as well as vagus nerve stimulation, which has shown some success for treating patients with rheumatoid arthritis [75] and Crohn’s disease [76], for protecting against cisplatin-mediated AKI. This evidence concerns the gene CHRNA7 and Crohn disease.